Castle Biosciences (CSTL) Net Income towards Common Stockholders (2018 - 2026)
Castle Biosciences (CSTL) posted Net Income towards Common Stockholders of -$2.1 million for Q2 2026, up 85.81% sequentially from -$14.5 million in Q1 2026, and down 145.21% YoY from $4.6 million in Q2 2025.
Castle Biosciences (CSTL) Net Income towards Common Stockholders (2018 - 2026) Analysis & Trends
Castle Biosciences has reported Net Income towards Common Stockholders for 9 years, with the latest figure at -$2.1 million in Q2 2026.
- Quarterly Net Income towards Common Stockholders fell 145.21% year-over-year to -$2.1 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$19.4 million (down 105.84% YoY) and the FY2025 annual result came in at -$24.2 million, down 232.41% from the prior year.
- Net Income towards Common Stockholders climbed to -$2.1 million in Q2 2026 per CSTL's latest filing, from -$14.5 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at $9.6 million in Q4 2024 and troughed at -$29.2 million in Q1 2023.
- A 5-year average of -$8.2 million and a median of -$2.6 million in 2023 frame the typical range for Net Income towards Common Stockholders.
- The sharpest annual moves came in 2023 and 2024: Net Income towards Common Stockholders slumped 1039.38% in 2023, then surged 471.71% in 2024.
- Over 5 years, Net Income towards Common Stockholders stood at -$20.6 million in 2022, then jumped by 87.49% to -$2.6 million in 2023, then soared by 471.71% to $9.6 million in 2024, then sank by 124.32% to -$2.3 million in 2025, then increased by 11.66% to -$2.1 million in 2026.
- According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$2.1 million, -$14.5 million, and -$2.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 213.88 Bn | 209.81 Bn | 8.34 Bn | 1.76 Bn |
| 2 | Danaher | 140.65 Bn | 136.30 Bn | 3.61 Bn | 870.00 Mn |
| 3 | Idexx Laboratories | 46.02 Bn | 45.83 Bn | 779.09 Mn | 338.41 Mn |
| 4 | Agilent Technologies | 39.85 Bn | 38.05 Bn | 990.00 Mn | 339.00 Mn |
| 5 | Iqvia Holdings | 39.20 Bn | 37.12 Bn | 1.44 Bn | 241.00 Mn |
| 6 | Natera | 38.80 Bn | 37.70 Bn | 696.04 Mn | -85.11 Mn |
| 7 | Illumina | 30.11 Bn | 28.94 Bn | 770.00 Mn | 207.00 Mn |
| 8 | Mettler Toledo International | 28.66 Bn | 28.61 Bn | 650.22 Mn | 232.90 Mn |
| 9 | Quest Diagnostics | 26.24 Bn | 25.61 Bn | 1.03 Bn | 324.00 Mn |
| 10 | Castle Biosciences | 926.56 Mn | 659.75 Mn | 79.85 Mn | -2.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.06 Mn |
| Mar 31, 2026 | -14.52 Mn |
| Dec 31, 2025 | -2.33 Mn |
| Sep 30, 2025 | -501,000.00 |
| Jun 30, 2025 | 4.56 Mn |
| Mar 31, 2025 | -25.85 Mn |
| Dec 31, 2024 | 9.59 Mn |
| Sep 30, 2024 | 2.27 Mn |
| Jun 30, 2024 | 8.92 Mn |
| Mar 31, 2024 | -2.53 Mn |
| Dec 31, 2023 | -2.58 Mn |
| Sep 30, 2023 | -6.91 Mn |
| Jun 30, 2023 | -18.78 Mn |
| Mar 31, 2023 | -29.20 Mn |
| Dec 31, 2022 | -20.62 Mn |
| Sep 30, 2022 | -20.25 Mn |
| Jun 30, 2022 | -1.65 Mn |
| Mar 31, 2022 | -24.62 Mn |
| Dec 31, 2021 | -13.38 Mn |
| Sep 30, 2021 | -11.79 Mn |